Q/C Technologies files late‑filing notice for 2025 10-K

Rhea-AI Filing Summary

Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) filed a Form 12b-25 notifying the SEC it cannot timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because it needs additional time to complete and finalize the required financial statements. The company states it currently anticipates filing the Form 10-K on or before the fifteenth calendar day following the prescribed due date. The notice is signed by Joshua Silverman, Executive Chairman, dated March 31, 2026.

Insights

Corporate Compliance Analyst

Routine late-filing notice citing additional time to finalize financials; anticipated short extension.

The filing invokes Rule 12b-25 and explains the company requires extra time to complete audited financial statements for the year ended December 31, 2025. The company anticipates filing within the 15 calendar day cure period allowed under the rule.

Key follow-ups: review the eventual Form 10-K for adjustments to results, auditor opinions, and any explanatory footnotes; timing and scope of any restatements or material changes will determine investor impact.

Key Figures

Fiscal year end: December 31, 2025 Cure period: 15 calendar days Notice signed date: March 31, 2026 +1 more

4 metrics

Fiscal year end December 31, 2025 year ended included in the delayed Form 10-K

Cure period 15 calendar days anticipated filing window under Rule 12b-25

Notice signed date March 31, 2026 signature date on the Form 12b-25

Contact telephone (856) 848-8698 telephone number provided on the form

Key Terms

Rule 12b-25, Form 10-K, Transition Report

3 terms

Rule 12b-25 regulatory

"unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-K regulatory

"its Annual Report on Form 10-K for the year ended December 31, 2025"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

Transition Report regulatory

"Transition Report on Form 10-K Transition Report on Form 20-F"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does QCLS's Form 12b-25 mean for the Form 10-K filing?

It notifies the SEC that Q/C Technologies needs more time to finalize audited financials. The company expects to file the Form 10-K within fifteen calendar days of the original due date. The notice explains the delay stems from completing and finalizing the required financial statements for year ended 2025.

When does Q/C Technologies expect to file the delayed 10-K (QCLS)?

The company anticipates filing the Form 10-K on or before the fifteenth calendar day after the prescribed due date. The notification cites Rule 12b-25 relief and identifies a 15 calendar day cure window. Exact calendar dates depend on the original filing deadline.

Who signed the Form 12b-25 for QCLS and when was it signed?

The notification was signed by Joshua Silverman, Executive Chairman. The signature block shows the date March 31, 2026. Contact information on the form lists a telephone number for follow-up inquiries.

Does a 12b-25 filing indicate financial restatements for QCLS?

No—this notice only states the company needs more time to finalize financial statements and does not assert any restatement. Any restatements or material changes would be disclosed in the subsequently filed Form 10-K itself.

Will the 12b-25 filing affect Q/C Technologies' reporting compliance status?

The filing preserves a short cure period under Rule 12b-25 and signals an anticipated timely cure within fifteen days. Continued non-filing beyond that period could change compliance status and trigger further SEC or exchange review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: December 31, 2025

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

Q/C Technologies, Inc.

Full Name of Registrant

TNF Pharmaceuticals, Inc.

Former Name if Applicable

1185 Avenue of the Americas, Suite 249

Address of Principal Executive Office (Street and Number)

New York, NY 10036

City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Q/C Technologies, Inc. (the “Company”) is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), because the Company requires additional time to complete and finalize its financial statements required to be included in the Form 10-K. The Company currently anticipates that the Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Joshua Silverman		856		848-8698
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
	Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Q/C Technologies, Inc.

(Name of registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	March 31, 2026		By:	/s/ Joshua Silverman
			Name:	Joshua Silverman
			Title:	Executive Chairman

3